The objective of this study was 2-fold: to evaluate whether phylogenetically closely related yeasts share common antifungal susceptibility profiles (ASPs) and whether these ASPs can be predicted from phylogeny. To address this question, 9,627 yeast strains were collected and tested for their antifungal susceptibility. Isolates were reidentified by considering recent changes in taxonomy and nomenclature. A phylogenetic (PHYLO) code based on the results of multilocus sequence analyses (large-subunit rRNA, small-subunit rRNA, translation elongation factor 1␣, RNA polymerase II subunits 1 and 2) and the classification of the cellular neutral sugar composition of coenzyme Q and 18S ribosomal DNA was created to group related yeasts into PHYLO groups. The ASPs were determined for fluconazole, itraconazole, and voriconazole in each PHYLO group. The majority (95%) of the yeast strains were Ascomycetes. After reclassification, a total of 23 genera and 54 species were identified, resulting in an increase of 64% of genera and a decrease of 5% of species compared with the initial identification. These taxa were assigned to 17 distinct PHYLO groups (Ascomycota, n ‫؍‬ 13; Basidiomycota, n ‫؍‬ 4). ASPs for azoles were similar among members of the same PHYLO group and different between the various PHYLO groups. Yeast phylogeny may be an additional tool to significantly enhance the assessment of MIC values and to predict antifungal susceptibility, thereby more rapidly initiating appropriate patient management.
T he taxonomy of fungi has been under significant discussion in recent years, in particular due to the molecular/sequence data that have become available. Fungi are classified primarily on the basis of the structures associated with sexual reproduction, which tend to be evolutionarily conserved. However, many fungi reproduce only asexually and cannot be assigned to a classification on the basis of sexual characteristics; some produce both asexual states (anamorphs/synanamorphs) and sexual states (teleomorph). These problematic species are often members of the Ascomycota, but they may also belong to the Basidiomycota. Even among fungi that reproduce both sexually and asexually, often only one method of reproduction can be observed at a specific point in time or under specific conditions (1) (2) (3) (4) (5) (6) .
The term "holomorph" has been assigned to fungi with teleomorphic sporulation, together with all their sporulating or vegetative anamorphs. This dual naming system can be confusing.
The former binomial nomenclature was according to the International Code of Botanical Nomenclature (ICBN), which is currently the International Code of Nomenclature for Algae, Fungi and Plants (ICNAFP) (7, 8) . Since 1 January 2013, only one name is allowed to be assigned to all newly described fungi, and the system permitting the use of separate names for anamorphs and teleomorphs was repealed (6) . In practice, the terms anamorph and teleomorph have been dropped in favor of the terms asexual stage and sexual stage, and all legitimate names proposed for a species, regardless of which reproduction stage they are typified by, can serve as the correct name for that species (5, 6, 9) . The usage of molecular tools has led to the recognition of many novel polymorphic and cryptic species (two or more distinct species classified as a single species) and species complexes, e.g., in Candida parapsilosis, Candida guilliermondii, Candida glabrata, and Aspergillus niger (10) (11) (12) (13) (14) (15) (16) (17) . To avoid uncertainties caused by fre-quent renaming and reassigning of human-pathogenic fungi, a plea with the aim of uncoupling molecular phylogeny from nomenclature was published by de Hoog et al. (18) . The authors stated that taxonomic novelties should be transferred into nomenclatural changes only when clinical relevance (e.g., different antifungal susceptibility patterns [ASPs] and/or virulence) is connected to it.
New molecular genetic identification techniques and the increased number of immunocompromised and severe ill patients have led to the identification and emergence of uncommon, rare, and novel species of opportunistic human and animal pathogens (19, 20) . The mortality rate due to yeast infections is still high (21) and may therefore reinforce the need for antifungal susceptibility testing in order to guide antifungal treatment. However, antifungal susceptibility testing takes time (Ͼ3 days), needs the fungus to be cultured, requires technical experience, and is not easily available in routine laboratories. In such cases, allocation to phylogenetic (PHYLO) groups may provide information sufficient for selection of the appropriate antifungal drugs.
The goal of this study was to evaluate whether phylogenetically closely related yeasts share common antifungal susceptibility patterns and whether the sensitivity of yeast pathogens to antifungals can be predicted from phylogeny. Thus, a large collection of clinically relevant yeasts from both the Ascomycota and Basidiomycota which had previously been collected in the framework of German/Austrian multicenter studies from 1998 to 2009 were reexamined. All strains investigated were studied for their phylogenetic relationship, were reassigned to valid species names according to recent taxonomic changes , and were evaluated for their antifungal susceptibility profiles.
MATERIALS AND METHODS
Yeast strains and antifungal susceptibility testing. A total of 15,606 clinical yeast isolates (Table 1) were collected by 39 participating study centers running four multicenter studies between November 1997 and January 2009. The participating centers were distributed throughout Germany and Austria. To avoid the bias of redundant data, multiple isolates obtained from an individual patient were eliminated. The final collection reanalyzed included 9,627 strains that were tested for susceptibility to the antifungal agents fluconazole (FLC), itraconazole (ITC), and voriconazole (VRC) using a microdilution assay (DIN 58940-84) (47, 48) . This method provides reproducible results similar to those obtained by the EUCAST procedure (48) (49) (50) (51) . Deutsches Institut für Normung (DIN) MIC distributions were in agreement with EUCAST MICs, and the data obtained were applied for EUCAST breakpoint setting (52) . In addition, the control limits of the MIC target values for FLC, ITC, and VRC MICs for control strain C. parapsilosis ATCC 22019 (American Type Culture Collection) were similar for the DIN and EUCAST (48, 53) . Also, Candida krusei (CL-CNM CL 3403) and Candida albicans (CL-CNM F 8555), both EUCAST quality control strains, displayed similar MIC ranges according to DIN standards (48, 50) . In 2002, DIN standards were replaced by EUCAST standards. The major difference is based on the fact that the DIN methodology recommended the usage of Heath-Robinson (HR) medium instead of RPMI 1640. At the time of the study, the individual test centers applying routine standard laboratory procedures performed the initial species identification, and species confirmation was performed using Fourier transform infrared spectroscopy (FT-IR). FT-IR has been reported to be a rapid, reliable, and cost-saving tool to identify and differentiate bacteria, dermatophytes, and yeasts (54) (55) (56) (57) (58) (59) (60) (61) (62) . An IFS 28/B spectrophotometer (Bruker GmbH, Germany) was used for FT-IRbased identification; the resulting spectra were transformed and evaluated using Opus software from Bruker GmbH, as previously described by Tietz et al. (58) . The reference was a comprehensive, validated in-house database consisting of at least one reference strain per yeast species (also including all known rare clinically relevant yeasts) from international collections, as follows: ). In addition, the database contains spectra for 3,264 clinical yeasts. Additionally, difficult-to-differentiate isolates were identified by an inhouse, panfungal PCR by a qualified reference laboratory selected by the multicenter study coordinators. The internal transcribed spacer (ITS) region was amplified using the primers ITS 1 (5=-TCC GTA GGT GAA CCT GCG G) and ITS 2 (5=-GCTGCG TTC TTC ATC GAT GC) (Metabion, Germany) as previously described by White et al. (63) . DNA was extracted from pure cultures using a DNeasy plant minikit (Qiagen) according to the manufacturer's instructions. PCR was performed on a TProfessioal standard thermocycler (Biometra), as previously described (64) . PCR products were purified using ExoSAP-IT (Affymetrix) enzymatic cleanup according to the manufacturer's instructions. DNA was sequenced by the use of primer ITS 1, a BigDye Terminator (version 3.1) cycle sequencing kit, and an ABI Prism 3100 genetic analyzer (Applied Biosystems). ITS sequences were identified using the NCBI BLAST sequence analysis search function (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Together with the origin (clinic/ward), the type of specimen investigated is given in Table S1 in the supplemental material. State-of-the-art taxonomy. All fungi were reevaluated according to the one-fungus, one-name principle, and new current valid species names were derived from the Index Fungorum (www.speciesfungorum.org), Mycobank (www.mycobank.org), and the database of the Fungal Biodiversity Centre (www.cbs.knaw.nl).
PHYLO code and PHYLO group. An easy computable artificial PHYLO code was developed to group all yeast isolates according to their phylogenetic relationships described elsewhere. The PHYLO code of ascomycetous yeasts takes into account (i) the 12 different clusters of Saccharomycetales obtained by multilocus sequence analyses of the largesubunit (LSU) rRNA, small-subunit (SSU) rRNA, translation elongation factor 1␣ (EF-1␣), RNA polymerase II subunit 1 (RPB1), and RPB2 genes, as described by Kurtzman and Robnett (22, 23) and Suh et al. (24) ; (ii) the classification according to the ubiquinone classification system, which considers the cellular neutral sugar composition of coenzyme Q (coenzyme Q) (44, 45) ; and (iii) the results of 18S ribosomal DNA (rDNA) analysis, which results in six clades (clades A to F), as described by Tsui et al. (29) , on the basis of the nucleotide sequences of the largest subunit and the second largest subunit of the RNA polymerase II gene, actin, the second subunit of the mitochondrial cytochrome oxidase gene, and the D1/D2 LSU rRNA gene.
Thus, the basis for the PHYLO code results from the presence of the main clusters of Kurtzman et al. (22) (clusters A1 to A9), the coenzyme Q classification (Q6 to Q9), and the clades (clades A to F) given by Tsui et al. (29) . As Exophiala dermatitidis strains belong to the ascomycetous yeast of the order Chaetothyriales, family Herpotrichiellaceae, and therefore are not covered by PHYLO codes A1 to A9, the artificial PHYLO code AH, which stands for Ascomycota and Herpotrichiellaceae, was assigned (Table 1 and Fig. 1 ). In addition, for further differentiation between galactose-containing and galactose-deficient species (57) , PHYLO group A9Q9G had to be introduced.
The PHYLO code of basidiomycetous yeasts was based on ribosomal DNA sequence (18S rDNA, SSU rRNA, D1/D2 of LSU rRNA, ITS region) (66), and Scorzetti et al. (67) . These have been designated B1 to B4 by use of the same ubiquinone (Co-Q) system (44, 45) used for the ascomycetous yeasts (Q8 to Q10). The current valid species names and their assigned PHYLO codes are provided in Table 1 and Fig. 1 .
RESULTS

Species classification.
Aside from the study center differentiations, identification of all yeasts by FT-IR was made at one study center, where this established method is performed routinely (60, 68) , relying on a database of almost 5,000 yeast species, including 495 strains from the American Type Culture Collection (ATCC), Deutsche Sammlung für Mikroorganismen (DSM; German Collection of Microorganisms), British National Collection of Type Cultures (NCTC), and Belgian Culture Collection of Microorganisms (BCCM). The initial identification (by the study centers) displayed 14 different genera with 56 different species; from the latter, 31 species were reported to be different Candida varieties. The application of the one-fungus, one-name principle and the reassignment of the new nomenclature resulted in an increase to 23 genera (64%) and in a reduction to 54 species (5%). Overall, 9,110 (95%) fungi were categorized as ascomycetous yeasts and 517 (5%) were identified as basidiomycetous yeasts. According to the reassessment, only 16 of the initial 31 Candida species could be truly assigned to the genus Candida (a decrease of 48%), while the other 15 previously reported species had to be reassigned to 11 distinct genera. In summary, a total of 14 new genus names were adopted (Table 1 ). Despite the fact that multiple species had to be reassigned to genera other than Candida, the genus Candida represented 70% of all 9,627 clinical isolates. Candida albicans remained the predominant yeast found in clinical specimens and was detected at a rate of 46%. Among the five most prevalent yeasts were C. glabrata (16.8%), Candida tropicalis (8.4%), Issatchenkia orientalis (7.4%), and C. parapsilosis (5.4%) ( Table 1) .
The specimens and the source (clinic/ward) from which the clinical isolates were derived are given in Table 2 . In this context, it should be mentioned that for the study centers and the collaborative in vitro testing, it was not mandatory to report the source of the isolated species. Therefore, much information (specimen type, source) was not disclosed and had to be marked not available.
Susceptibility data for the five most frequent Candida species and non-Candida species are given in Table 3 . Among the basidiomycetous yeasts most commonly encountered were Cryptococcus neoformans (3.3%), Malassezia furfur (0.6%), and Trichosporon asahii (0.5%) ( Table 1 ). The isolation frequencies of all individual species, together with their valid names, synonyms, and the assigned PHYLO codes, are given in Table 1 .
PHYLO groups. Applying the phylogenetic relationships of all distinct entities published by Kurtzman and Robnett (22, 23) and Suh et al. (24) , their five main clusters, designated A1, A2, A5, A6, and A9, covered all 9,059 yeast isolates associated with the Saccharomycetales (phylum Ascomycota, subphylum Saccharomycotina, class Saccharomycetes, order Saccharomycetales).
All species in PHYLO group A9Q9 (yeasts sharing this PHYLO code) contained only Co-Q9 as the major ubiquinone. The artificial subgroup G of A9Q9 does not refer to a different Co-Q system; however, it had to be introduced to distinguish between galactosecontaining and galactose-deficient species (57) . By further dis-crimination, all 9,110 ascomycetous yeasts could be assigned to a total of 13 PHYLO groups ( Fig. 1 and Table 1 ). The 517 basidiomycetous yeasts were assigned to four different PHYLO groups, referred to as PHYLO codes B1 to B4 ( Fig. 1 and Table 1 ). In total, all 9,627 clinical isolates were phylogenetically separated into 17 PHYLO groups. Together with Candida africana, Candida dubliniensis, Candida membranifaciens, C. parapsilosis, and C. tropicalis, C. albicans formed the largest PHYLO group (A1Q9A), covering 5,841 strains (Tables 1 and 3) . The smallest PHYLO group within the Ascomycota was A1Q9C, consisting only of Hanseniaspora uvarum (n ϭ 3). A complete summary of all species and their association with the different PHYLO groups is given in Fig. 1 and Tables 1 and 3 .
Antifungal susceptibility. According to the reassessment, the MICs of the five most frequently isolates Candida and non-Candida species are given as cumulative percentages in Table 3 , with MIC 50 and MIC 90 values indicated by shadowed numbers. Four of the five listed Candida species in Table 3 belonged to PHYLO group A1Q9A, whereas C. glabrata was affiliated with PHYLO group A1Q6F. In addition, Kluyveromyces marxianus and Saccharomyces cerevisiae belonged to this group. The two PHYLO groups A1Q9A and A1Q6F covered 72% of all strains and represented the two main clusters with major importance for the clinical setting.
The MIC values for the PHYLO groups are given in Tables S2 and  S3 in the supplemental material. Similar to the findings for the different species, the phylogenetic groups varied in their antifungal susceptibility profiles. A remarkable finding was that strains within an individual PHYLO group shared similar susceptibility profiles. Furthermore, it turned out that the PHYLO group which encompassed the majority of yeasts (A1Q9A) had MIC 50 values for all tested azoles (FLC MIC 50 ϭ 0.5 mg/liter, ITC MIC 50 ϭ 0.031 mg/liter, VRC MIC 50 ϭ 0.031 mg/liter) distinctly lower than those for the second largest group, A1Q6F (FLC MIC 50 ϭ 4.0 mg/liter, ITC MIC 50 ϭ 0.25 mg/liter, and VRC MIC ϭ 0.125 mg/ liter) ( Table 2 ). This indicates that isolates in group A1Q9A are the most susceptible to FLC, ITC, and VRC. Isolates in all other PHYLO groups demonstrated higher MIC 50 values for all tested azoles, with the exception of A6Q8B, which had the same low MIC 50 value for VRC as A1Q9A. The Basidiomycota in PYHLO group B4Q10 were the most resistant to ITC (MIC 50 , 1.0 mg/liter). Members of PHYLO group A1Q9B were the most resistant to FLC (MIC 50 , 32.0 mg/liter). Overall, VRC was the most active drug in vitro against the members of the majority of the PHYLO groups, including all Basidiomycota (PHYLO groups B1 to B4), and the ascomycetous yeasts in PHYLO groups A1Q6F, A1Q9B, A2Q7E, A6Q8B, and AHQ10. VRC and ITC were equally effective against the isolates in the remaining groups.
The species-related characteristic MIC values of PHYLO groups A1Q6F, A1Q9A, and A5Q7D, containing the majority of the isolates, are displayed in Table 4 . They clearly demonstrate that the MIC profiles differed significantly. For these three ascomycetous PHYLO groups, statistical analysis was performed as an example to assess the association between phylogenetically determined yeast groups and their in vitro MICs. As MIC data were not normally distributed, comparison of MICs between PHYLO groups was performed with the Mann-Whitney U test ( Table 4 ). The test confirmed that the results for the three groups of related isolates were highly significantly different (P Ͻ 0.001). Despite the fairly large database, rare species were represented only by disproportionally low numbers of strains compared with the numbers for the most common yeast species. Due to the low number of strains of some species associated with different ascomycetous and basidiomycetous PHYLO groups, only characteristic MIC values (mean MIC, mode MIC, MIC 50 , MIC 75 , MIC 90 ) were calculated. However, they explicitly demonstrated that these PHYLO groups were also clearly separated (no significant correlation between MICs of PHYLO groups), as their MIC profiles differed significantly (see Tables S4 and S5 in the supplemental material).
This finding is additionally supported by the determination of their antifungal susceptibility patterns (ASPs) (49) . The susceptibility patterns for multiresistant isolate populations harboring parallel and cross-resistant strains are displayed in Table 5 , which explicitly demonstrates the different susceptibility and resistance profiles of the isolates in the various PHYLO groups.
DISCUSSION
Application of the state-of-the-art taxonomy to the fungal database investigated indicates that C. albicans is still the predominant yeast, found at a rate of 46% in clinical specimens. Aside from C. albicans, among the five most prevalent yeasts are C. glabrata (16.8%), C. tropicalis (8.4%), Issatchenkia orientalis (7.4%), and C. parapsilosis (5.4%). This reflects the internationally observed distribution of yeast species, indicating changes in epidemiology with a certain shift to uncommon fungi documented by a number of retrospective and prospective analyses by surveillance networks and single institutions (69, 70) . This change and the increase in the incidence of rare fungal etiological agents not only is due to the increasing number of immunocompromised patients (71, 72) but also is due to newly described species and the reclassification of isolates according to the changing taxonomy. New species are continuously recognized to be of clinical importance, and new species may arise from the splitting of pervious species complexes into two or more distinct species (description of sibling species, e.g., C. parapsilosis and C. glabrata). This trend is additionally supported by the use of molecular genetic identification methods and modern fingerprinting techniques (e.g., infrared spectroscopy, nuclear magnetic resonance, mass spectrometry). So far, available therapeutic options are limited, particularly for emerging and drug-resistant pathogens. In vitro antifungal susceptibility testing may help to select the most appropriate therapeutic agent.
The study presented herein indicates that phylogenetically closely related yeast pathogens share common antifungal susceptibility patterns. As shown by their percentages of higher MIC values, ascomycetous non-albicans Candida species may play a significant role in resistance to azoles (Tables 3 and 4 ). In addition, the phylogenetic comparisons clarify the inhomogeneous MIC profiles of the previous Candida clade, which included most of the ascomycetous yeasts. Thus, as also shown by the susceptibility patterns (Table 4 ), each PHYLO group may be recognized by its antifungal susceptibility/resistance profile. Furthermore, the MIC differences between the Candida species included non-albicans Candida isolates (e.g., PHYLO groups A5Q7D, A1Q6F, and A6Q8B), and the true Candida species (PHYLO groups A1Q9A/A1Q9B) became even more prominent when the one-fungus, one-name principle was applied to analyze their phylogenetic relationships. Nevertheless, given that C. albicans isolates from around the world could be assigned to 1 of 17 homogeneous clade clusters (73) , by revealing that C. albicans, C. dubliniensis, C. tropicalis, and the C. parapsilosis complex made up the main cluster, this phylogenetically tightly related Candida clade (20, 74, 75) may be called the true Candida species, with C. albicans being its type species, which may therefore be referred to as Candida sensu stricto. The term non-C. albicans (NAC) should comprise Candida species phylogenetically outside this Candida clade, and they may be referred to as Candida sensu lato.
The delineation of the basidiomycetous yeasts on the basis of DNA/RNA sequence analysis is still not completely resolved, as the anamorphic genera Cryptococcus, Rhodotorula, and Sporobolomyces are present in more than one phylogenetic group. Basid- B3Q10 (74, 13) B4Q10 (22, 9) All strains (9, 627, 24) iomycetes were grouped (38, 43, (65) (66) (67) into four artificial clades, B1 to B4, to which the appropriate PHYLO groups were assigned ( Fig. 1; Tables 1 and 3 ). The isolates of Trichosporon spp. had to be transferred to two PHYLO groups, B1Q10 and B2Q9, because of their different predominant Co-Q enzymes. Incorporating in vitro antifungal susceptibility test data into PHYLO groups may have an important impact upon the selection of antifungal agents for therapy, especially for rare or new opportunistic fungal pathogens whose sensitivity to antifungal drugs is unknown. For this, a prerequisite is to correctly identify and discriminate isolates down to the species level. I. orientalis, Pichia norvegensis, Pichia cactophila, and Pichia fermentans cluster in one PHYLO group (A5Q7D), and as demonstrated here, both species C. krusei and P. norvegensis have high MIC values for FLC (76) . Similar MIC values were obtained for Candida, Cryptococcus, and other yeast species, including isolates that exhibited resistance to FLC and ITC, e.g., isolates in PHYLO group A1Q9B. This corresponds with the MIC data reported by Cuenca-Estrella et al. (77) . In addition, aside from FLC, the MICs of the different PHYLO groups matched quite well for VRC and ITC, when the MICs for the different Candida, non-C. albicans, and non-Candida clusters were compared.
Some limitations of this study have to be mentioned. First, although all isolates were tested according to a common protocol and the same methodology, MIC results may differ slightly from those published by others (e.g., an MIC 50 of 0.5 g/ml for C. albicans compared to the MIC obtained by CLSI). However, this does not influence the main message that related yeasts share similar MICs. Our fungi were collected over a period of 12 years, and the majority were derived from severe ill patients, including HIVinfected patients. We assume that most of these cohorts received azole treatment, and the higher MICs presented herein may in turn reflect this treatment. It is important to note that during the 1990s, fluconazole MICs for C. albicans and other Candida spp. were generally higher than those of other antifungal agents (78, 79) , as observed nowadays. Emergent resistance to azole drugs was a serious problem until the introduction of highly active antiretroviral therapy for the treatment of HIV. Second, phylogenetic and ubiquinone evaluation of all species encountered in this study is not yet fully resolved. Therefore, bias in the appropriate attribution to an individual PHYLO group may occur. Third, although a large number of strains of some rare yeasts was included, the case numbers were too low and too unbalanced compared to those for the major yeast species (e.g., C. albicans and C. glabrata) to allow adequate statistical significance testing. The results per PYHLO group might be driven by C. albicans and C. glabrata and do not allow a clear statement regarding the groups with smaller numbers of isolates. Estimates of MIC 50 s and MIC 90 s are unstable and influenced by the unbalanced case numbers. However, the large differences in the prevalence of the different species in our study represent the situation in clinical practice. Additionally, when excluding the data for the two most frequent species, C. albicans and C. glabrata, in a sensitivity analysis, there were still significant differences between the three main PHYLO groups (A1Q6F, A1Q9A, A5Q7D) and for ITR (all had P values of Ͻ0.01) and FLC (all had P values of Ͻ0.002); the main message therefore remains. Although closely related isolates, e.g., C. albicans and C. dubliniensis, could be clearly separated (77, 80) and showed a high probability of developing resistance to azoles (80) (81) (82) , as reported in the literature, the MICs of C. dubliniensis may differ significantly (80) . For example, despite the low numbers of C. dubliniensis iso-lates tested and the relatedness of C. dubliniensis to C. albicans, it could be demonstrated that C. dubliniensis, like other species, shows its own distinct group of susceptibility profiles. This was supported by susceptibility pattern analysis ( Table 5 ). As the PHYLO group provides general information on the antifungal susceptibility profiles of several yeast populations, the possibility that strains resistant to individual or multiple agents are present cannot be excluded.
SPA and statistical analysis ( Table 5; see Tables S4 and S5 in the supplemental material) clearly indicate that there are distinct differences among the different PHYLO groups rather than differences among the most common Candida species.
In conclusion, ascomycetous and basidiomycetous species may vary significantly phylogenetically, and this diversity is mirrored by the different antifungal susceptibility profiles of the different PHYLO groups. In this respect, from the susceptibility profiles of the PHYLO groups of the basidiomycetous yeasts compared to those of the PHYLO groups of the ascomycetous yeasts, it can be seen that, in general, the Basidiomycetes demonstrate profiles with higher MIC values than the Ascomycetes. This is in agreement with the data reported by Desnos-Ollivier et al. (19) , who reported higher MIC values for Basidiomycota reference strains than for Ascomycota reference strains. The approach that combined the phylogenetic relatedness and the ubiquinone system in the PHYLO code was beneficial for the discrimination of the different PHYLO groups. Therefore, as already shown with the three azoles (FLC, ITC, VRC), for which a fairly large database of antifungal susceptibility patterns for different species was available, it could be demonstrated that phylogenetically closely related yeasts share common antifungal susceptibility patterns, and it is feasible that phylogeny can be used as an additional tool to predict the resistance/sensitivity of yeast pathogen groups to antifungal agents.
